药用芍药发明专利格局与发展分析  

Profile of the Invention Patents of Paeonia lactiflora Pall

作　　者：王秋玲[1,2] 马运运 孙云波[1,2] 王晓东[2,3] 孙志一 刘海波[1,2] 

机构地区：[1]中国医学科学院北京协和医学院药用植物研究所,北京100193 [2]国家中医药管理局传统药物专利信息资源重点研究室,北京100080 [3]北京东方灵盾科技有限公司,北京100080

出　　处：《世界科学技术-中医药现代化》2014年第7期1476-1481,共6页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：国家自然科学基金青年项目(3130272):基于功能基因时空表达研究赤芍和白芍功效成分差异的形成机制;负责人:王秋玲;中国博士后科学基金委一般项目(2013M530557):基于分子谱系地理学研究赤芍品种选育;负责人:王秋玲

摘　　要：芍药药用历史悠久,被广泛运用于制药、食品及化妆品工业。本文对芍药在医药方面的发明专利进行检索,得到18 192件专利数据集,在此基础上进行了多角度的统计分析。结果显示,我国药用芍药发明专利申请数量远超其他国家,企业专利权人占主体;我国专利的技术质量不高、国际化保护比例较低;与芍药配伍的传统中药多具有补益保健功能。在治疗功效的开发利用方面,心血管疾病和肝病的治疗是未来研究重点,特别需要加大剂型方面的研究力度。资源综合利用方面,对芍药花和种子的开发利用具有较大的拓展空间。本研究可以帮助科研工作者了解药用芍药当前的研究成果和专利格局,把握未来研究方向。Paeonia lactiflora Pall. has a long history of utilization, and is widely used in pharmaceutical, food and cosmetic industry. In this paper, the invention patents of traditional medicine P. lactiflora before 2014 were retrieved, and totally 18 192 patent families were obtained. And we formed the patent analysis report of medicine P. lactiflora based on a multi-angle analysis. Results show that, as to the patent number of medicine P. lactiflora, China is much more than any other country, and the applications mainly came from pharmaceutical enterprises. But the technological quality of patents and international protection ratio are low in our country. We need to strengthen in treatment of cardiovascular and liver disease. The patents mainly focused on the use of tonic health, which is compatible with Traditional Chinese Medicine. On the product development, dosage forms need to be enhanced. As to the comprehensive utilization of resources, the flower and seed of P. lactiflora have relatively larger research space and value. This work will be helpful for researchers in deeply understanding the research achievements of medicine P. lactiflora, and provides the reference data for the future research.

关 键 词：芍药 传统药物 专利文献 数据库 

分 类 号：G255.53[文化科学—图书馆学]